Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Deals

Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services

Fineline Cube Dec 20, 2022

Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake...

Company Drug

CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment

Fineline Cube Dec 20, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...

Company Drug

Ascletis Pharma Receives USPTO Notice for ASC10 Patent

Fineline Cube Dec 20, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...

Company Drug

HutchMed Initiates Rolling NDA Submission for Elunate to US FDA

Fineline Cube Dec 20, 2022

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...

Legal / IP Policy / Regulatory

PCAOB Report Signals Relief for US-Listed Chinese Biotechs

Fineline Cube Dec 20, 2022

A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...

Company Deals

Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange

Fineline Cube Dec 19, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially...

Company Drug

Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial

Fineline Cube Dec 19, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...

Company Drug

Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment

Fineline Cube Dec 19, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...

Company Drug

TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody

Fineline Cube Dec 19, 2022

China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...

Company Deals Drug

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Fineline Cube Dec 19, 2022

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company Drug

Jiangsu Recbio’s Herpes Zoster Vaccine REC610 Gets Clinical Trial Approval in Philippines

Fineline Cube Dec 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced receiving clinical trial...

Company Deals

Endo International Licenses TLC’s Phase III Nanomedicine for OA Knee Pain

Fineline Cube Dec 19, 2022

Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo...

Company Drug

GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor

Fineline Cube Dec 19, 2022

China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...

Company Medical Device

Blue Sail Medical’s Microcatheter Receives NMPA Marketing Approval

Fineline Cube Dec 19, 2022

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced obtaining marketing approval from the...

Company Deals

Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland

Fineline Cube Dec 19, 2022

China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider,...

Company Deals

InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao

Fineline Cube Dec 19, 2022

InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen,...

Company

Novartis China Establishes Health Development Fund in Boao Lecheng

Fineline Cube Dec 19, 2022

Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...

Company Drug

Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC

Fineline Cube Dec 16, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...

Company Deals

XingImaging and Mitro Biotech Partner for Contract Research Services in China

Fineline Cube Dec 16, 2022

US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide...

Posts pagination

1 … 522 523 524 … 603

Recent updates

  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
  • Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.